PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.06
0.06 - 0.24
8.7K / 3.59M (Avg.)
-1.55 | -0.04
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
691.16%
G&A growth while CRN.AX reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
503.99%
Operating expenses growth while CRN.AX reduces costs. John Neff would investigate differences.
503.99%
Total costs growth while CRN.AX reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
56.16%
D&A growth while CRN.AX reduces D&A. John Neff would investigate differences.
-381.38%
EBITDA decline while CRN.AX shows 6.09% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-80.45%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
268.19%
Other expenses growth above 1.5x CRN.AX's 71.85%. Michael Burry would check for concerning trends.
1251.82%
Pre-tax income growth exceeding 1.5x CRN.AX's 55.66%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
376.57%
Tax expense growth while CRN.AX reduces burden. John Neff would investigate differences.
5682.20%
Net income growth exceeding 1.5x CRN.AX's 47.33%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
5320.00%
EPS growth exceeding 1.5x CRN.AX's 47.22%. David Dodd would verify competitive advantages.
5326.67%
Diluted EPS growth exceeding 1.5x CRN.AX's 47.31%. David Dodd would verify competitive advantages.
4.50%
Share count increase while CRN.AX reduces shares. John Neff would investigate differences.
4.34%
Diluted share change of 4.34% while CRN.AX is stable. Bruce Berkowitz would verify approach.